Insmed | INSM - Selling And Administration Expenses


Insmed reported $247.47M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Cytokinetics USD 104.4M 499K Jun/2026
DBV Technologies USD 13.4M 8.14M Mar/2026
Gilead Sciences USD 1.52B 70M Jun/2026
Heron Therapeutics USD 23.74M 605K Dec/2025
Insmed USD 247.47M 208K Jun/2026
Novartis USD 3.14B 296M Mar/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026